Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEPHEN G SWISHER and NEDA KALHOR.
STEPHEN G SWISHER
Connection Strength
1.509
NEDA KALHOR
  1. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.180
  2. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol. 2023 01; 36(1):100028.
    View in: PubMed
    Score: 0.055
  3. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28.
    View in: PubMed
    Score: 0.053
  4. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
    View in: PubMed
    Score: 0.051
  5. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.048
  6. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 2020 11 04; 21(1):271.
    View in: PubMed
    Score: 0.047
  7. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.045
  8. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.045
  9. Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nat Cancer. 2020 04; 1:423-436.
    View in: PubMed
    Score: 0.045
  10. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.045
  11. The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clin Cancer Res. 2020 02 15; 26(4):892-901.
    View in: PubMed
    Score: 0.044
  12. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. Am J Respir Crit Care Med. 2019 09 15; 200(6):742-750.
    View in: PubMed
    Score: 0.044
  13. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48.
    View in: PubMed
    Score: 0.040
  14. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2018 04 01; 29(4):1072.
    View in: PubMed
    Score: 0.039
  15. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791.
    View in: PubMed
    Score: 0.039
  16. Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Mod Pathol. 2018 06; 31(6):947-955.
    View in: PubMed
    Score: 0.039
  17. Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. Oncotarget. 2018 Mar 06; 9(18):14268-14284.
    View in: PubMed
    Score: 0.039
  18. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
    View in: PubMed
    Score: 0.039
  19. Nuclear expression of Gli-1 is predictive of pathologic complete response to chemoradiation in trimodality treated oesophageal cancer patients. Br J Cancer. 2017 Aug 22; 117(5):648-655.
    View in: PubMed
    Score: 0.038
  20. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2017 Autumn; 29(3):408-415.
    View in: PubMed
    Score: 0.037
  21. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Rep. 2017 05 23; 19(8):1669-1684.
    View in: PubMed
    Score: 0.037
  22. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up. Ann Oncol. 2017 01 01; 28(1):75-82.
    View in: PubMed
    Score: 0.036
  23. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function. Ann Oncol. 2017 01 01; 28(1):83-89.
    View in: PubMed
    Score: 0.036
  24. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289.
    View in: PubMed
    Score: 0.035
  25. Genomic Landscape Established by Allelic Imbalance in the Cancerization Field of a Normal Appearing Airway. Cancer Res. 2016 07 01; 76(13):3676-83.
    View in: PubMed
    Score: 0.035
  26. RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer. Oncotarget. 2015 May 10; 6(13):11114-24.
    View in: PubMed
    Score: 0.032
  27. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science. 2014 Oct 10; 346(6206):256-9.
    View in: PubMed
    Score: 0.031
  28. Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer. Lung Cancer. 2014 Jul; 85(1):88-93.
    View in: PubMed
    Score: 0.030
  29. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014 Jan; 15(1):e42-50.
    View in: PubMed
    Score: 0.029
  30. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma. Clin Cancer Res. 2013 Dec 01; 19(23):6556-65.
    View in: PubMed
    Score: 0.029
  31. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res. 2013 Nov 15; 19(22):6261-71.
    View in: PubMed
    Score: 0.029
  32. Visceral pleural invasion is not predictive of survival in patients with lung cancer and smaller tumor size. Ann Thorac Surg. 2013 Jun; 95(6):1872-7; discussion 1877.
    View in: PubMed
    Score: 0.028
  33. Early-stage pulmonary adenocarcinoma (T1N0M0): a clinical, radiological, surgical, and pathological correlation of 104 cases. The MD Anderson Cancer Center Experience. Mod Pathol. 2013 Aug; 26(8):1065-75.
    View in: PubMed
    Score: 0.028
  34. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2013 Feb; 8(2):222-8.
    View in: PubMed
    Score: 0.028
  35. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
    View in: PubMed
    Score: 0.027
  36. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol. 2012 May; 7(5):825-32.
    View in: PubMed
    Score: 0.026
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.